Form 4 Filing for Jay Backstrom

Jay Backstrom, a director at Agios Pharmaceuticals, Inc., acquired 2,927 restricted stock units and 14,950 stock options on June 18, 2026. The restricted stock units represent a contingent right to receive one share of common stock each and will vest in full on June 18, 2027. The stock options, with an exercise price of $34.16, also vest fully on June 18, 2027. All transactions were reported on a Form 4 filing dated June 23, 2026.